| Literature DB >> 2519197 |
Abstract
The appropriate sample size for a clinical trial depends on the objectives of the trial. For Phase II trials, the recommended sample size is generally in the neighborhood of 25-40 patients, regardless of the choice of design. Sample sizes for Phase III trials are much more variable, ranging from less than a hundred to thousands of patients. The methodology of sample size determination for Phase III trials depends on the type of endpoint that is to be the primary focus of analysis. Tables of sample sizes for a variety of situations are presented. Use of sequential designs may reduce the required sample size by permitting early termination of trials whose results become definitive prior to completion of patient entry.Entities:
Mesh:
Year: 1989 PMID: 2519197
Source DB: PubMed Journal: Oncology (Williston Park) ISSN: 0890-9091 Impact factor: 2.990